Radiographic Outcomes Were Associated with Pain and Function Responses: Post-Hoc Analysis of Results from a Phase 2 Study of a Small Molecule Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment

被引：0

作者：

Yazici, Yusuf ^{[1
]}

McAlindon, Timothy E. ^{[2
]}

Gibofsky, Allan ^{[3
,4
]}

Lane, Nancy E. ^{[5
]}

Skrepnik, Nebojsa ^{[6
]}

Armas, Eddie ^{[7
]}

Swearingen, Christopher J. ^{[1
]}

DiFrancesco, Anita ^{[1
]}

Tambiah, Jeymi ^{[1
]}

Hochberg, Marc ^{[8
,9
]}

机构：

[1] Samumed LLC, San Diego, CA USA

[2] Tufts Med Ctr, Div Rheumatol, Boston, MA USA

[3] Weill Cornell Med, Rheumatol, New York, NY USA

[4] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA

[5] Univ Calif Davis, Sch Med, Ctr Musculoskeletal Hlth, Sacramento, CA 95817 USA

[6] Tuscon Orthoped Inst, Tucson, AZ USA

[7] Well Pharma Med Res, Miami, FL USA

[8] Univ Maryland, Sch Med, Div Rheumatol & Clin Immunol, Baltimore, MD 21201 USA

[9] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1204

引用

页数：2

共 50 条

[21] Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor in Knee Osteoarthritis
Conaghan, Philip G.
DiFrancesco, Anita
Swearingen, Christopher J.
Kennedy, Sarah
Simsek, Ismail
Tambiah, Jeymi
Yazici, Yusuf
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[22] Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee
Swearingen, Christopher J.
Majumdar, Sharmila
Simsek, Ismail
DiFrancesco, Anita
Tambiah, Jeymi
Yazici, Yusuf
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[23] RADIOGRAPHIC OUTCOMES FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR, INJECTABLE, WNT PATHWAY INHIBITOR (SM04690) IN THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE: WEEK 26 INTERIM ANALYSIS
Yazici, Y.
McAlindon, T. E.
Gibofsky, A.
Lane, N. E.
Skrepnik, N.
Armas, E.
Swearingen, C. J.
DiFrancesco, A.
Tambiah, J. R.
Hochberg, M. C.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 121 - 121
[24] COMPARISON OF INTRA-ARTICULAR SHAM AND VEHICLE INJECTION FROM A PHASE 2B TRIAL OF SM04690, A SMALL-MOLECULE WNT INHIBITOR, FOR KNEE OSTEOARTHRITIS
Yazici, Y.
Tambiah, J.
Swearingen, C.
Kennedy, S.
Strand, V.
Cole, B.
Hochberg, M.
Bannuru, R.
McAlindon, T.
OSTEOARTHRITIS AND CARTILAGE, 2019, 27 : S241 - S242
[25] THE NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR LORECIVIVINT (SM04690), A WNT PATHWAY MODULATOR, IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS FROM A PHASE 2B TRIAL
Tambiah, J.
Kennedy, S.
Swearingen, C.
Yazici, Y.
OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S45 - S46
[26] Results from a 52 Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis
Yazici, Yusuf
McAlindon, Timothy E.
Gibofsky, Allan
Lane, Nancy E.
Clauw, Daniel J.
Armas, Eddie
Skrepnik, Nebojsa
Swearingen, Christopher J.
DiFrancesco, Anita
Tambiah, Jeymi
Hochberg, Marc
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[27] RESULTS FROM A 52-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR WNT PATHWAY INHIBITOR (SM04690) FOR THE TREATMENT OF KNEE OSTEOARTHRITIS
Yazici, Y.
McAlindon, T. E.
Gibofsky, A.
Lane, N. E.
Clauw, D. J.
Jones, M. H.
Bergfeld, J.
Swearingen, C. J.
DiFrancesco, A.
Tambiah, J. R.
Hochberg, M.
OSTEOARTHRITIS AND CARTILAGE, 2018, 26 : S293 - S294
[28] The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Yazici, Yusuf
Kennedy, Sarah
Swearingen, Chris
Tambiah, Jeyanesh
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[29] THE NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR LORECIVIVINT (LOR; SM04690), WHICH MODULATES THE WNT PATHWAY, IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS FROM A PHASE 2B TRIAL
Yazici, Y.
Kennedy, S.
Swearingen, C.
Tambiah, J.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 809 - 810
[30] RESULTS FROM A 52-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDYOFA NOVEL, INTRA-ARTICULAR WNT PATHWAY INHIBITOR (SM04690) FOR THE TREATMENT OF KNEE OSTEOARTHRITIS
Yazici, Y.
McAlindon, T.
Gibofsky, A.
Lane, N.
Clauw, D.
Grifman, M.
Swearingen, C.
DiFrancesco, A.
Tambiah, J.
Hochberg, M.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S137 - S137

← 1 2 3 4 5 →